The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 09, 1996
Filed:
Apr. 14, 1994
Edward W Martin, Jr, Delaware, OH (US);
The Ohio State University Research Foundation, Columbus, OH (US);
Abstract
Broadly, the present invention is directed to a method for reliably staging adenocarcinomas typified by colorectal cancer in patients who are undergoing surgery therefor. The method includes the administration of a radiolabeled tumor-associated glycoprotein (TAG) antibody (or other equivalent locator) to the cancer patient prior to surgical accession of the patient. Desirably, the present method includes surgical accession with a radiation detection probe for determining tissue exhibiting elevated levels of radiation. The preferred radiolabel is .sup.125 I, which is used to label an antibody specific to a high molecular weight glycoprotein called TAG-72. The preferred antibody is CC49, a murine monoclonal antibody of the IgG.sub.1 subclass. With radiolabeled monoclonal antibody CC49, it preferably is administered to the patient approximately 21 days (.+-.4 days) prior to surgery. Following surgical excision of all such tissue which is amenable to excision, the probe is again used to identify any remaining neoplastic tissue or tissue deposits, which may or may not be subjected to further excision attempts. After all possible excision of neoplastic tissue has occurred, final counts are taken with the probe to identify residual tissue deposits not excised. The number and location of the remaining tissue deposits form the basis of the biostaging system disclosed herein.